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Abstract: The neuronal voltage-gated N-type calcium channel (Cav2.2) is a validated 
target for the treatment of neuropathic pain. A small library of anthranilamide-derived  
ω-Conotoxin GVIA mimetics bearing the diphenylmethylpiperazine moiety were prepared 
and tested using three experimental measures of calcium channel blockade. These 
consisted of a 
125
I-ω-conotoxin GVIA displacement assay, a fluorescence-based calcium 
response assay with SH-SY5Y neuroblastoma cells, and a whole-cell patch clamp 
electrophysiology assay with HEK293 cells stably expressing human Cav2.2 channels. A 
subset of compounds were active in all three assays. This is the first time that compounds 
designed to be mimics of ω-conotoxin GVIA and found to be active in the 125I-ω-conotoxin 
GVIA displacement assay have also been shown to block functional ion channels in a  
dose-dependent manner. 
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1. Introduction 
Neuropathic pain, a pathology of the nervous system, is often highly debilitating and is thought to 
affect up to one-sixth of the world’s population [1]. There are numerous causes for the condition, 
including nerve damage resulting from surgery, trauma, infection and disease. This type of pain can be 
unresponsive to existing therapies. A combination of opioids, antidepressants and anticonvulsants is 
often prescribed, but usually only provides moderate pain relief and only in about 50% of cases [2,3], 
thus effective treatments for neuropathic pain represent a significant unmet medical need. Neuronal 
voltage-gated N-type calcium channels (Cav2.2) are strongly implicated in chronic and neuropathic 
pain, but there are only three approved pain-blocking drugs that act on this channel; gabapentin, 
pregabalin and ziconotide [1]. Small molecule inhibitors of Cav2.2 are potential leads for the treatment 
of neuropathic pain and have therefore been widely pursued in industry and academia [4–6].  
Recent reports include those from Neuromed Pharmaceuticals (now Zalicus) [7–10], Abbott [11–13],  
Merck [14,15] and Janssen [16], with Neuromed’s NMED-160 reaching Phase II trials before being 
voluntarily withdrawn due to bioavailability issues. Reformulation of NMED-160, by Zalicus, gave 
Z160 which has now successfully completed Phase I trials. Phase II trials are due to commence in the 
second half of 2012 [10]. 
The ω-conotoxins are a family of calcium channel-blocking cystine knot peptides found in the 
venom of fish-hunting marine cone snails [17–19]. The most widely studied Cav2.2 blockers from this 
class are ω-conotoxins GVIA, MVIIA and CVID. Ziconotide (also known as Prialt) is a synthetic 
version of ω-conotoxin MVIIA and is used in the clinic as a primary alternative to opioids for the 
management of intractable chronic pain. While this drug does not appear to lead to tolerance, its 
intrathecal delivery, narrow therapeutic index and side effect profile means that it suffers from high 
dropout rates and is far from an ideal treatment [20]. ω-Conotoxin CVID is more selective for Cav2.2 
channels and is expected to have greater therapeutic potential. This peptide reached Phase II in 2004 
and is still being investigated under the name Leconotide [21,22]. Of the three peptides, ω-conotoxin 
GVIA has the highest affinity for the Cav2.2 channel, but its virtual irreversible binding makes it 
unattractive as a therapeutic drug. The highly constrained nature of these peptides and the availability 
of SAR data make them ideal starting points for the development of peptidomimetics [23,24]. Mimics 
of all three of these peptides have been developed, beginning with the work of Horwell and co-workers 
at Parke-Davis, who prepared three-residue non-peptidic mimics of ω-conotoxin MVIIA based on a 
phloroglucinol core [25–27]. Subsequently, Lewis’ group developed a cyclic pentapeptide that mimics 
the action of ω-conotoxin CVID [28]. We have been investigating non-peptidic mimics of ω-conotoxin 
GVIA based on benzothiazole [29,30] and anthranilamide [31,32] cores. These mimics, which bear 
tyrosine, lysine and arginine side chain mimics projected from a central scaffold were designed based 
on Bartlett and Lauri’s Cα-Cβ bond vector philosophy, but—crucially—not involving automated 
scaffold retrieval but rather interactive de novo design [23,24,33]. 
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An investigation of the mimic based on the anthranilamide scaffold involved variation of the length 
of the side chains, the incorporation of two guanidino moieties, and two variations of the diphenyl 
ether substituent (see Figure 1) [32]. Key findings from this study were that; (a) typically diguanidino 
compounds [Z = N=(NH2)2] had binding activity in the 6–16 μM range in a radio-labelled ω-conotoxin 
GVIA displacement assay, whereas diamino compounds [Z = NH2] bound more weakly and; (b) 
strongest affinity was found with a fluorinated mimic [X = F].  
Figure 1. Previously described ω-conotoxin mimics based on an anthranilamide  
scaffold [32]. 
 
There are a number of compounds that effectively block voltage-gated calcium channels that bear 
the diphenylmethylpiperazine moiety [34]. Relevant to the current study are Neuromed’s NP-118809 
(NMED-160) [7,8] and Abbott’s A-1048400 [11,12] shown in Figure 2. It was thus decided to prepare 
analogues of the anthranilamide-based conotoxin mimics where a diphenylmethylpiperazine moiety 
was incorporated in place of the phenoxyaniline substituent (Figure 3), and test their ability to block 
neuronal calcium channels in non-functional and, importantly, functional assays.  
Figure 2. Recently published Cav2.2 blockers bearing the diphenylpiperazine moiety. 
 
Figure 3. Analogues targeted in this study. 
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2. Results and Discussion 
2.1. Chemistry 
The previously described synthetic route to the anthranilamide-based mimics [32] was modified to 
allow incorporation of the diphenylmethylpiperazine moiety at a later stage in the synthesis, thus 
facilitating the preparation of a small library of compounds from a common, advanced precursor. This 
advanced precursor was the diazide (5), which was prepared in four steps from the previously reported 
nitro ester (1) [32], as shown in Scheme 1. This involved reduction of the nitro compound (1) to the 
aniline (2), acylation with 6-bromohexanoyl chloride to give the dihalide (3), conversion to the diazide (4) 
with in situ-formed tetra-n-butyl ammonium azide [35], and cleavage of the t-butyl ester. 
Scheme 1. Reagents and conditions: (a) H2, Pd/C, ethanol; (b) 6-bromohexanoyl chloride, 
Triethylamine (Et3N), Dichloromethane (CH2Cl2); (c) Trimethylsilylazide (TMS-N3), 
Tetrabutylammonium fluoride (TBAF), Tetrahydrofuran (THF); (d) Trifluoroacetic acid 
(TFA), THF. 
 
A small set of compounds was prepared in which the phenoxyaniline substituent of the original 
anthranilamide-based mimics was replaced with fluorinated and unfluorinated diphenylmethylpiperazine, 
1,3-benzodioxomethylpiperazine and phenylmethylpiperidine substituents. The latter two substituents 
were chosen to test the importance of the presence of the diphenylmethyl functionality to Cav2.2 
activity. The required diamines (7a–d) and diguanidino compounds (8a–d) were prepared from  
diazido acid (5) in three steps, as shown in Scheme 2. This involved the use of a DCC-assisted 
amidation protocol described by Shpiro and Marquez [36] to give 6a–d, reduction of the azide 
functionalities with dithiothreitol [37], to give 7a–d, and guanidine formation by treatment with  
1H-pyrazole-carboxamidine [38] to give 8a–d. 
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Scheme 2. Reagents and conditions: (a) Dicyclohexylcarbodiimide (DCC), 
Hydroxybenzotriazole (HOBt), Dimethylformamide (DMF), cyclic secondary amine, 
Diisopropylethylamine (DIPEA), DMF/THF (1:1); (b) dithiothreitol, Et3N, methanol;  
(c) 1H-pyrazole-carboxamidine hydrochloride, DIPEA, DMF. For 6a–8a,  
X = (Ph)2CH-N; for 6b–8b, X = (4-F-Ph)2CH-N; for 6c–8c, X = Ph-CH; for 6d–8d,  
X = 1,3-Benzodioxolan-5-yl-CH2-N. 
 
2.2. Biology 
2.2.1. Radioligand Displacement Assay 
The synthesized compounds, diamino (7a–d) and diguanidinium (8a–d), were initially evaluated for 
their ability to bind to rat brain Cav2.2 channels using a previously described radioligand displacement 
assay [29–32,39], employing 125I-labelled ω-conotoxin GVIA. Although not a functional assay, the 
high selectivity of ω-conotoxin GVIA for Cav2.2 channels means that compounds able to displace  
125
I-labelled ω-conotoxin GVIA from rat brain homogenate are likely to be functional inhibitors of 
Cav2.2 channels. The results obtained with 7a–d and 8a–d are summarized in Table 1.  
The affinities of the compounds that lack the diphenylmethyl functionality (7c, 7d, 8c and 8d) were 
too weak to be measured by this method, whereas those that do possess that moiety (7a, 7b, 8a and 8b) 
showed moderate to good binding (see Figure 4). As observed previously with this class of  
compound [32], the diguandino compounds (8a and 8b) showed strongest binding, comparable to 
some of the best reported anthranilamides [32], determined by this method. Compounds 7a, 7b, 8a and 
8b were therefore selected for follow-up functional assays. 
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Table 1. Cav2.2 binding affinities of diamino (7a–d) and diguanidinium (8a–d) 
anthranilamides, as determined by displacement of 
125
I-GVIA from rat brain homogenate 
(95% confidence intervals are shown in parentheses). 
Figure 4. Dose-response curves for the displacement of 
125
I-GVIA from rat brain 
homogenate by diamino (7a and 7b) and diguanidinium (8a and 8b) compounds.  
cpm = counts per minute. 
 
2.2.2. Inhibition of Neuroblastoma Intracellular Calcium Responses, Determined by Fluorescence 
Measurement of Calcium Flux 
The abilities of the diamino (7a and 7b) and diguanidinium (8a and 8b) compounds to inhibit 
intracellular calcium responses in SH-SY5Y human neuroblastoma cells, in the presence of the L-type 
calcium channel blocker nifedipine were assessed using a high-throughput Ca
2+
 fluorescence assay. It 
was found that Ca
2+
 ion channel responses elicited by KCl-mediated depolarization were partially 
 
Diamino 
compound 
EC50 Cav2.2 
(μM) 
Diguanidinium 
compound 
EC50 Cav2.2 
(μM) 
 
7a 214 (160–290) 8a 12 (9–15) 
 
7b 65 (50–83) 8b 16 (13–20) 
 
7c weak 8c weak 
 
7d weak 8d weak 
7a 
8a 
7b 
8b 
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inhibited by the test compounds at concentrations which did not produce fluorescence addition 
artefacts (100 µM; Figure 5A), with compound 7b being less efficacious (4.9 ± 1.8% inhibition) than 
compounds 7a (23.1 ± 1.5% inhibition), 8a (20.3 ± 4.0% inhibition) and 8b (24.4 ± 1.5% inhibition). 
While these inhibitory effects are not strong, dose-dependent inhibition was observed (Figure 5B) 
which allowed the estimation of IC50’s for the functional inhibition of intracellular calcium responses 
in SH-SY5Y human neuroblastoma cells. These results are shown in Table 2. The estimated IC50s 
from these functional, whole-cell experiments are up to an order of magnitude weaker than those 
obtained from the radioligand displacement assay. A similar shift in potency is observed with the  
ω-conotoxins, whose effectiveness is reduced in the presence of physiological Ca2+ levels [40] and 
auxiliary subunits [41], which are likely to dissociate from the Cav α-subunit in membrane preparations 
used in radioligand displacement assays. It is also plausible that the decreased potency of the test 
compounds in the functional assays, in addition to effects of co-expressed auxiliary subunits, may have 
been influenced by relatively short incubation times in the presence of extracellular divalent cations, 
which has been reported to affect the on-rate of ω-conotoxin block. 
Figure 5. Inhibition of calcium responses from SH-SY5Y human neuroblastoma cells  
by diamino (7a and 7b) and diguanidinium (8a and 8b) compounds. (A) Calcium  
channel-mediated Ca
2+
 transients were partially inhibited by pre-treatment with compounds 7a, 
8a and 8b at 100 µM. (B) Dose-response curves for functional inhibition of calcium responses.  
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Table 2. Estimated IC50 values (μM; mean ± SEM) for the functional inhibition of calcium 
channels by compounds 7a, 7b, 8a and 8b. 
Compound 
SH-SY5Y 
neuroblastoma cells 
HEK293 
hCav2.2 + β3 + α2δ1 
7a 160 ± 3.6 232 ± 23 
7b 286 ± 66 288 ± 49 
8a 206 ± 50 299 ± 43 
8b 156 ± 10 156 ± 21 
Despite giving comparable radioligand displacement assay results to the best previously reported 
anthranilamides (see Figure 1) [32], the new diphenylmethylpiperazine-substituted compounds  
(7a, 8a and 8b) showed superior inhibition of intracellular calcium responses in SH-SY5Y cells  
(data not shown) and hence can be considered an improvement on previous designs.  
2.2.3. Patch-Clamp Electrophysiology Experiments with HEK293 Cells Expressing Cav2.2  
Calcium Channels 
SH-SY5Y human neuroblastoma cells contain a number of calcium channel subtypes [42–45]. To 
specifically measure the effect of the diamino (7a and 7b) and diguanidinium (8a and 8b) 
anthranilamides on N-type (Cav2.2) calcium channel currents, electrophysiological patch-clamp studies 
were carried out on HEK293 cells stably expressing human Cav2.2 (a1 + β3 + α2δ1 subunits). 
Compounds 7a, 7b and 8a were each tested at two concentrations (30 and 100 µM), whereas 8b was 
only tested at 30 µM. Representative traces obtained prior to compound application (Control) and 
following application of compound 7a at 30 and 100 µM are shown in Figure 6A. The time course of 
washing in and out of compound 7a is shown in Figure 6B, with peak current amplitude being 
measured at 10 s intervals. All four compounds showed a modest inhibition of the calcium current 
amplitude; 10%–17% at 30 µM and 20%–27% at 100 µM (Figure 6C), while exhibiting no shift in the 
G–V relationship or changes to channel inactivation. To determine an approximate IC50 value, the data 
were fit assuming that these compounds completely inhibited the calcium currents, with a Hill 
coefficient of −1. This gave the predicted half-maximal inhibition (IC50’s) shown in Table 2 and are 
consistent with those obtained using the FLIPR-Ca
2+
 assay in SH-SY5Y cells. The estimated IC50 
values for 8b obtained from the two techniques are in close agreement and, of all the compounds 
examined in this study, this compound appears to most effectively block Cav2.2 calcium channels. 
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Figure 6. Effects of diamino (7a and 7b) and diguanidinium (8a and 8b) anthranilamides 
on Cav2.2 currents in HEK293 cells. (A) Superimposed whole-cell calcium currents obtained 
from HEK293 cells stably expressing N-type calcium channels (hCav2.2 + β3 + α2δ1), 
with depolarizing voltage steps from a holding potential of −80 mV to a test potential of 
+20 mV (150 ms). Representative currents are shown prior to compound 7a application 
(Control) and in the presence of compound 7a at two concentrations (30 and 100 µM).  
(B) Time course of inhibition of peak inward current in response to 30 and 100 µM 
compound 7a. (C) Bar graph of the relative inhibition of peak current amplitude  
(1 − Icompound/Icontrol) for each compound at concentrations of 30 and 100 µM (number of 
experiments in parentheses). 
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3. Experimental Section  
3.1. Chemistry 
3.1.1. General Experimental Procedures 
Starting materials and reagents were purchased from Sigma-Aldrich and used without purification. 
Tetrahydrofuran (THF) was distilled under a nitrogen atmosphere from sodium benzophenone ketal. 
Dry DCM was obtained after drying over 3 Å sieves. Methanol and DMF were obtained by passage 
through two alumina columns on the Solvent Dispensing System built by J. C. Meyer and based on the 
original design by Grubbs and co-workers [46]. Solutions were dried over anhydrous magnesium 
sulfate (MgSO4) or sodium sulfate (Na2SO4). Normal phase flash chromatography was performed on 
Merck silica gel No. 9385 and reverse phase chromatography was performed using a C18 
Chromatorex
®
 DM1020T column (30 × 40 mm). Spectra were recorded on a Bruker Av200 or Av400 
spectrometer. Unless otherwise stated, proton (
1
H) NMR spectra were acquired at 200 MHz and 
carbon (
13
C) NMR spectra at 50 MHz. NMR spectra were referenced to residual solvent peak 
[chloroform (δH 7.26, δC 77.0), methanol (δH 4.87, 3.30, δC 49.86)]. The units for all coupling constants (J) 
are in hertz (Hz). Low resolution mass spectra were recorded on a Micromass Platform spectrometer or 
VG Platform spectrometer. Accurate mass determinations were carried out at high resolution on an 
Agilent G1969A LC-TOF system, with reference and mass correction at 4000 V capillary voltage for ESI.  
3.1.2. Synthesis 
tert-Butyl-2-amino-5-(3-chloropropoxy)benzoate (2)  
To a vigorously stirred flask containing tert-butyl-5-(3-chloropropoxy)-2-nitrobenzoate [32] 1 (5.17 g, 
16.4 mmol) in ethanol (100 mL), was added 10% wt palladium on carbon (0.17 g). The reaction 
mixture was flushed with hydrogen (3×) and then stirred under an atmosphere of hydrogen for 15 h. 
The reaction mixture was filtered through Celite, the Celite thoroughly rinsed with methanol and the 
combined organics concentrated in vacuo. The residue was taken up in diethyl ether (150 mL) and washed 
with water and brine, then dried (MgSO4) and concentrated to afford the title compound as an oil (4.18 g, 
89%). This compound was used in subsequent transformations without further purification. δH (CDCl3) 
1.62 (s, 9H), 2.25 (m, 2H), 3.75 (t, J = 6.2 Hz, 2H), 4.15 (t, J = 6.0 Hz, 2H), 7.17 (dd, J = 3.0, 8.8 Hz, 1H), 
7.52 (d, J = 3.0 Hz, 1H), 7.90 (d, J = 8.8 Hz, 1H); δC (CDCl3) 28.1, 31.9, 41.1, 64.9, 84.5, 117.3, 119.9, 
123.8, 125.7, 127.0, 158.0, 166.0; m/z (EI
+
): m/z (%): 285.1 (30) [M]
+
, 229.0 (100) [M − C4H9]
+
. 
tert-Butyl-2-(6-bromohexanamido)-5-(3-chloropropoxy)benzoate (3)  
6-Bromohexanoyl chloride (2.1 mL, 14 mmol) was added dropwise to the aniline 2 (3.72 mg,  
13.0 mmol) and triethylamine (2.7 mL, 19 mmol) dissolved in dry DCM (70 mL). The reaction 
mixture was stirred at RT for 20 h and then poured into 2 M HCl (50 mL). The layers were separated 
and the aqueous phase was extracted with DCM. The combined organic phases were washed with 
saturated sodium bicarbonate and brine, then dried (MgSO4) and concentrated in vacuo to afford the 
amide 3 as an oil (6.02 g, quant.); δH (CDCl3) 1.49–1.99 (complex, 6H), 1.61 (s, 9H), 2.23 (m, 2H), 
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2.44 (t, J = 7.2 Hz, 2H), 3.42 (t, J = 6.8 Hz, 2H), 3.75 (t, J = 6.2 Hz, 2H), 4.11 (t, J = 6.0 Hz, 2H), 7.08 
(dd, J = 3.0, 9.2 Hz, 1H), 7.47 (d, J = 3.0 Hz, 1H), 8.62 (d, J = 9.2 Hz, 1H), 10.93 (br s, 1H). δC 
(CDCl3) 24.6, 27.7, 28.2, 32.2, 32.5, 33.5, 38.2, 41.4, 64.7, 82.6, 116.3, 117.7, 120.2, 121.8, 135.4, 153.3, 
167.3, 171.3; m/z (ESI
+
, 50 eV): m/z (%): 486.0 (100) [M + Na]
+
, 484.0 (70), 464 [M + H]
+
, 462.0 (20). 
tert-Butyl-2-(6-azidohexanamido)-5-(3-azidopropoxy)benzoate (4)  
The diazide 4 was prepared from the dihalide 3 (5.92 g, 12.8 mmol) by treatment with 
trimethylsilylazide (95% purity, 5.4 mL, 39 mmol) and tetra-n-butylammonium fluoride (1.0 M in 
THF, 38.4 mL, 38.4 mmol) in THF following the method of Takaya [35]. Care was taken to ensure the 
diazide was not subjected to shock or heat. The diazide 4 was obtained as a light brown oil which was 
purified by flash chromatography (20: 1 DCM/MeOH) to afford a cream-colored solid (4.09 g, 74%). 
δH (CDCl3) 1.40–1.85 (complex, 6H), 1.59 (s, 9H), 2.02 (m, 2H), 2.42 (t, J = 7.2 Hz, 2H), 3.26  
(t, J = 6.6 Hz, 2H), 3.50 (t, J = 6.6 Hz, 2H), 4.02 (t, J = 5.8 Hz, 2H), 7.05 (dd, J = 3.2, 9.2 Hz, 1H), 
7.44 (d, J = 3.2 Hz, 1H), 8.60 (d, J = 9.2 Hz, 1H), 10.92 (br s, 1H); δC (CDCl3) 25.0, 26.3, 28.1, 28.6, 
28.7, 38.2, 48.1, 51.2, 64.9, 82.6, 116.2, 117.6, 120.2, 121.8, 135.4, 153.2, 167.2, 171.3; m/z (ESI
+
, 50 eV): 
m/z (%): 454.6 (15) [M + Na]
+
, 432.7 (100) [M + H]
+
.  
2-(6-Azidohexanamido)-5-(3-azidopropoxy)benzoic acid (5)  
To a solution of 4 (1.31 g, 3.05 mmol) in dry DCM (10 mL) was added TFA (10 mL) dropwise. 
After stirring the reaction mixture at RT for 4 h it was poured into water (20 mL) and extracted with 
DCM (2 × 10 mL). The organic phase was dried, and concentrated in vacuo to yield the title compound 
as a solid (1.14 g, 99%). δH (CDCl3) 1.43–1.87 (complex, 6H), 2.05 (m, 2H), 2.48 (t, J = 7.2 Hz, 2H), 
3.28 (t, J = 6.6 Hz, 2H), 3.52 (t, J = 6.4 Hz, 2H), 4.06 (t, J = 5.8 Hz, 2H), 7.16 (dd, J = 3.0, 9.2 Hz, 
1H), 7.61 (d, J = 3.0 Hz, 1H), 8.64 (d, J = 9.2 Hz, 1H), 10.86 (br s, 1H); δC (CDCl3) 25.1, 26.2, 28.5, 
28.7, 38.1, 48.1, 51.2, 65.0, 116.0, 116.6, 121.6, 122.1, 172.2, 135.3, 153.7, 170.9; m/z (ESI
+
, 50 eV): 
m/z (%): 398.6 (100) [M + Na]
+
, 376.5 (70) [M + H]
+
. 
6-Azido-N-(4-(3-azidopropoxy)-2-(4-benzhydrylpiperazine-1-carbonyl)phenyl)hexanamide (6a)  
The title compound was prepared following an amidation procedure used by Marquez and Shpiro [36]. 
To a solution of the diazide 5 (120 mg, 0.33 mmol) in anhydrous THF and DMF (1:1, 3.2 mL) was 
added DCC (100 mg, 0.49 mmol). After the reaction mixture was stirred at RT for 15 min, HOBt (70 mg, 
0.49 mmol) and 4-DMAP (8 mg, 0.06 mmol) were added. After 1.5 h, 1-benzhydrylpiperazine (170 mg, 
0.65 mmol) and DIPEA (0.17 mL, 0.98 mmol) were sequentially added. After stirring at RT for 24 h, 
the mixture was filtered, the precipitate washed with DCM and solvent was removed in vacuo. 
Purification by flash chromatography (3:1 PET spirit 40–60/ethyl acetate) gave the title compound 6a 
as a solid (130 mg, 66%); δH (CDCl3) 1.40–1.80 (complex, 6H), 2.01 (m, 2H), 2.32 (t, J = 7.2 Hz, 2H), 
2.40 (br s, 4H), 3.30 (t, J = 6.6 Hz, 2H), 3.48 (t, J = 6.6 Hz, 2H), 3.71 (br s, 4H), 3.98 (t, J = 6.0 Hz, 
2H), 4.26 (s, 1H), 6.70 (d, J = 2.8 Hz, 1H), 6.89 (dd, J = 3.0, 9.0 Hz, 1H), 7.15–7.43 (m, 10H), 8.01  
(d, J = 8.0 Hz, 1H), 8.49 (br s, 1H); δC (CDCl3) 25.1, 26.3, 28.6, 28.7, 37.3, 48.1, 51.2, 51.9 (br), 52.1 (br), 
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65.0, 75.9, 113.4, 116.0, 125.0, 126.5, 127.2, 127.8, 128.6, 129.6, 141.9, 154.4, 168.3, 171.1;  
m/z (ESI
+
, 50 eV): m/z (%): 632.3 (10) [M + Na]
+
, 610.3 (50) [M + H]
+
.  
6-Azido-N-(4-(3-azidopropoxy)-2-(4-(bis(4-fluorophenyl)methyl)piperazine-1-carbonyl) 
phenyl)hexanamide (6b)  
The title compound 6b was prepared from 5 and 1-(bis(4-fluorophenyl)methyl)piperazine according 
to the procedure used to prepare 6a, except that the reaction mixture was stirred at RT for 56 h. 
Purification by flash chromatography (2:1 PET spirit 40–60/ethyl acetate) gave 6b (140 mg, 85%). δH 
(CDCl3) 1.39–1.79 (m, 6H), 2.01 (m, 2H), 2.31 (t, J = 7.6 Hz, 2H), 2.36 (br s, 4H), 3.29 (t, J = 6.8 Hz, 
2H), 3.48 (t, J = 6.4 Hz, 2H), 3.73 (br s, 4H), 3.98 (t, J = 6.0 Hz, 2H), 4.24 (s, 1H), 6.68 (d, J = 2.8 Hz, 
1H), 6.89 (dd, J = 2.8, 9.0 Hz, 1H), 6.92–7.02 (m, 4H), 7.29–7.36 (m, 4H,), 7.95 (d, J = 9.0 Hz, 1H), 
8.50 (br s, 1H); δC (CDCl3) 25.1, 26.3, 28.6, 28.7, 37.2, 48.1, 51.2, 51.7 (br), 65.0, 74.2, 113.4, 115.6 
(d, J = 21.6 Hz), 116.0, 125.3, 126.8, 129.1, 129.2 (d, J = 7.9 Hz), 137.4 (d, J = 3.0 Hz), 154.5, 161.9 
(d, J = 246.5 Hz), 168.4, 171.2; m/z (ESI
+
, 50 eV): m/z (%): 668.3 (10) [M + Na]
+
, 646.3 (35) [M + H]
+
. 
6-Azido-N-(4-(3-azidopropoxy)-2-(4-phenylpiperidine-1-carbonyl)phenyl)hexanamide (6c)  
The title compound 6c was prepared from 5 and 4-phenylpiperidine according to the procedure used 
to prepare 6a. Purification by flash chromatography (1:1 PET spirit 40–60/ethyl acetate) gave 6c (190 mg, 
93%); δH (CDCl3) 1.37–2.00 (methylene envelope, 10H), 2.02 (m, 2H), 2.32 (t, J = 6.0 Hz, 2H), 2.78 
(m, 1H), 3.00 (br s, 2H), 3.25 (t, J = 6.0 Hz, 2H), 3.49 (t, J = 6.0 Hz, 2H), 4.01 (t, J = 6.0 Hz, 2H), 4.80 
(br s, 2H), 6.76 (d, J = 2.0 Hz, 1H), 6.90 (dd, J = 2.0, 6.0 Hz, 1H), 7.17–7.32 (m, 5H), 7.90 (d, J = 8.0 Hz, 
1H), 8.63 (s, 1H); δC (CDCl3) 24.8, 25.0, 26.2, 28.5, 28.6, 33.3 (br), 33.8, 37.0, 42.3, 48.0, 51.1, 64.9, 
113.0, 115.8, 125.4, 126.5, 127.6, 128.5, 129.1, 144.6, 154.6, 168.4, 171.1; m/z (ESI
+
, 50 eV): m/z (%): 
541.3 (100) [M + Na]
+
, 519.3 (20) [M + H]
+
. 
6-Azido-N-(4-(3-azidopropoxy)-2-(4-((3a,7a-dihydrobenzo[d][1,3]dioxol-5-yl)methyl) 
piperazine-1-carbonyl)phenyl)hexanamide (6d)  
The title compound 6d was prepared from 5 and 1-piperonylpiperazine according to the procedure 
used to prepare 5. Purification by flash chromatography (5:1 PET spirit 40–60/ethyl acetate) gave 6d 
(200 mg, 54%); δH (400 MHz, CDCl3) 1.43 (m, 2H), 1.59–1.74 (methylene envelope, 4H), 2.02 (m, 2H), 
2.30 (t, J= 7.6 Hz, 2H), 2.41 (br s, 2H), 2.47 (br s, 2H), 3.27 (t, J = 6.8 Hz, 2H), 3.44 (s, 2H), 3.49  
(t, J = 6.8Hz, 2H), 3.75 (br s, 4H), 4.00 (t, J = 6.0 Hz, 2H), 5.92 (s, 2H), 6.70–6.72 (m, 3H), 6.83  
(s, 1H), 6.89 (dd, J = 2.8, 8.8 Hz, 1H), 7.91 (d, J = 8.8 Hz, 1H), 8.52 (s, 1H); δC (100 MHz, CDCl3) 
25.1, 26.3, 28.6, 28.7, 37.2, 48.1, 51.2, 52.6 (br), 53.0 (br), 62.4, 65.0, 101.0, 108.0, 109.4, 113.3, 
116.1, 122.3, 125.4, 127.0, 129.4, 130.9, 146.9, 147.8, 154.6, 168.4, 171.2; HRMS (ES
+
) [M + H]
+
 
calcd for C28H36N9O5 578.2839 found 578.2829. 
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6-Amino-N-(4-(3-aminopropoxy)-2-(4-benzhydrylpiperazine-1-carbonyl)phenyl)hexanamide (7a)  
A solution of 6a (140 mg, 0.22 mmol) in methanol (4.5 mL) was treated sequentially with 
dithiothreitol (20 mg, 1.3 mmol) and TEA (0.1 mL, 0.9 mmol). After the reaction mixture was stirred 
at room temperature for 20 h, the solvent was removed in vacuo. Purification by reverse phase 
chromatography [elution with methanol/water (90:10, 60 mL), followed by methanol (75 mL) and then 
acetonitrile (30 mL)] gave 7a (60 mg, 52%); δH (methanol-d4) 1.35–1.60 (complex, 4H), 1.69 (m, 2H), 
1.91 (m, 2H), 2.33 (complex, 4H), 2.45 (m, 2H), 2.67 (br t, J = 6.8 Hz, 2H), 2.82 (br t, J = 6.9 Hz, 2H), 
3.38 (br s, 2H), 3.71 (br s, 2H), 4.04 (br t, J = 6.2 Hz, 2H), 4.30 (s, 1H), 6.82 (d, J = 2.8 Hz, 1H), 6.98 
(dd, J = 2.8, 8.8 Hz, 1H), 7.18–7.29 (m, 7H,), 7.43 (d, J = 6.9 Hz, 4H); δC (methanol-d4) 26.8, 27.6, 
33.2, 33.3, 37.2, 39.6, 42.3, 43.2, 49.9, 52.6, 53.1, 67.5, 77.2, 114.1, 117.2, 128.3, 129.0, 129.1, 129.7, 
133.9, 143.7, 158.3, 170.0, 171.2; m/z (ESI
+
, 50 eV): m/z (%): 558.3 (100) [M + H]
+
, 570.3 (30)  
[M + Na]
+
. HRMS (ESI
+
) [M + H]
+
 calcd for C33H44N5O3 558.3444 found 558.3460.  
6-Amino-N-(4-(3-aminopropoxy)-2-(4-(bis(4-fluorophenyl)methyl)piperazine-1-carbonyl) 
phenyl)hexanamide (7b)  
The diamine 7b was prepared from 6b according to the procedure used to prepare 7a. The product 
was isolated as an oil (90 mg, 75%). δH (methanol-d4) 1.36–1.75 (methylene envelope, 6H), 1.91 (m, 
2H), 2.31 (t, J = 7.4 Hz, 2H), 2.42 (br s, 4H), 2.66 (t, J = 7.0 Hz, 2H), 2.80 (t, J = 7.0 Hz, 2H), 3.38 (br s, 
2H), 3.70 (br s, 2H), 4.03 (t, J = 6.0 Hz, 2H), 4.35 (s, 1H), 6.81 (d, J = 2.6 Hz, 1H), 6.94–7.05 (m, 5H), 
7.26 (d, J = 8.8 Hz, 1H), 7.38–7.45 (m, 4H); δC (methanol-d4) 26.7, 27.5, 32.9, 33.0, 37.1, 39.5, 42.1, 
43.1, 52.4, 52.7, 67.5, 75.2, 114.1, 116.3 (d, J = 21.5 Hz), 117.0, 129.0, 130.7 (d, J = 7.9 Hz), 133.7, 
139.4 (d, J = 3.1 Hz), 158.2, 163.3 (d, J = 244.3 Hz), 169.9, 175.0; m/z (ESI
+
, 50 eV): m/z (%): 594.3 
(100) [M + H]
+
. HRMS (ESI
+
) [M + H]
+
 calcd for C33H42N5O3F2 (M + H)
+
 594.3256 found 594.3259. 
6-Amino-N-(4-(3-aminopropoxy)-2-(4-phenylpiperidine-1-carbonyl)phenyl)hexanamide (7c)  
The diamine 7c was prepared from 6c according to the procedure used to prepare 7a. Purification by 
reverse phase chromatography [elution with methanol/water (80:20)] gave 7c as an oil (120 mg, 99%); 
δH (400 MHz, methanol-d4) 1.39–1.60 (methylene envelope, 4H), 1.72 (m, 4H), 1.95 (m, 2H), 2.37  
(m, 2H), 2.68 (m, 2H), 2.80–2.91 (complex, 5H), 3.17 (br s, 2), 3.76 (br d, J = 13.2 Hz, 1H), 4.07  
(t, J = 6.0 Hz, 2H), 4.74 (d, J = 12.0 Hz, 1H), 6.90 (s, 1H), 7.01 (dd, J = 2.4, 8.4 Hz, 1H),7.18–7.43  
(m, 6H); δC (methanol-d4) 25.3, 26.1, 31.1, 31.4, 32.7, 33.3, 35.7, 38.1, 40.6, 42.2, 66.1, 112.5, 115.5, 
126.1, 126.4, 126.8, 127.7, 128.2, 132.8, 145.3, 156.9, 168.5, 173.6; m/z (ESI
+
, 50 eV): m/z (%): 467.3 
(100) [M + H]
+
, 489.3 (55) [M + Na]
+
.  
6-Amino-N-(4-(3-aminopropoxy)-2-(4-(benzo[d][1,3]dioxol-5-ylmethyl)piperazine-1-carbonyl) 
phenyl)hexanamide (7d)  
The diamine 7d was prepared from 6d according to the procedure used to prepare 7a. The product 
was isolated as an oil (90 mg, 61%); δH (methanol-d4) 1.37–1.76 (methylene envelope, 6H), 1.94 (m, 
2H), 2.32 (t, J = 7.2 Hz, 2H), 2.39 (br s, 2H), 2.50 (br s, 2H), 2.70 (t, J = 6.8 Hz, 2H), 2.84 (t, J = 6.8 Hz, 
2H), 3.36 (br s, 2H), 3.47 (s, 2H), 3.70 (br s, 2H), 4.06 (t, J = 6.0 Hz, 2H), 5.91 (s, 2H), 6.75 (br s, 2H), 
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6.82 (br s, 2H), 7.00 (dd, J = 2.8, 8.8 Hz, 1H), 7.28 (d, J = 8.8 Hz, 1H); δC (methanol-d4) 25.3, 26.1, 
31.2, 31.5, 35.7, 38.1, 40.6, 41.4, 52.0, 52.3, 62.0, 66.1, 100.9, 107.4, 109.2, 112.6, 115.7, 122.4, 
126.8, 127.7, 130.8, 132.4, 147.0, 147.8, 156.9, 168.5, 173.7; m/z (ESI
+
, 50 eV): m/z (%): 526.4 (20) 
[M + Na]
+
, 477.3 (30) [M + H]
+
. HRMS (ES
+
) [M + H]
+
 calcd for C28H39N5O5 526.3029 found 526.3018. 
N-2(4-Benzhydrylpiperazine-1-carbonyl)-4-(3-guanidinopropoxy) 
phenyl-6-guanidinohexanamide dihydrochloride (8a)  
The diguanidinium compound 8a was prepared following the general procedure of  
Bernatowitcz et al. [21]. To the amine 7a (50 mg, 0.09 mmol) in DMF (0.2 mL) was added  
1H-pyrazole-carboxamidine hydrochloride (30 mg, 0.17 mmol) and DIPEA (0.03 mL, 0.17 mmol) and 
the reaction mixture was stirred at RT for 68 h. The solvent was then removed in vacuo and the residue 
triturated with diethyl ether to give a solid that was recrystallized from ether/methanol to afford 8a as a 
glassy semisolid (45 mg, 74%); δH (methanol-d4) 1.49 (m, 2H), 1.67 (m, 4H), 2.04 (m, 2H), 2.32–2.46 
(complex, 6H), 3.18–3.42 (methylene envelope, 6H), 3.71 (br s, 2H), 4.07 (t, J = 5.6 Hz, 2H), 4.32 (s, 
1H), 6.86 (d, J = 2.6 Hz, 1H), 7.02 (dd, J = 2.8, 8.8 Hz, 1H), 7.11–7.33 (m, 8H), 7.43 (br d, J = 7.0 Hz, 
3H); δC (methanol-d4) 26.4, 27.2, 29.6, 36.9, 39.6, 42.4, 43.2, 52.6, 53.0, 66.6, 77.2, 114.3, 117.2, 
121.4, 128.3, 128.5, 129.0, 129.7, 133.9, 143.7, 158.1, 158.7, 158.8, 170.0, 175.0; m/z (ESI
+
, 50 eV): 
m/z (%): 642.5 (100) [M + H]
+
. HRMS (ESI
+
) [M + H]
+
 calcd for C35H48N9O3 642.3880 found 642.3885. 
N-2-(4-(Bis(4-fluorophenyl)methyl)piperazine-1-carbonyl)-(4-(3-guanidinopropoxy) 
phenyl)guanidinohexanamide dihydrochloride (8b)  
The diguanidinium compound 8b was prepared from the diamine 7b according to the method used 
to prepare 8a. The product 8b was obtained as a semiglassy solid (90 mg, 84%); δH (methanol-d4) 
1.40–1.55 (methylene envelope, 2H) 1.55–1.80 (methylene envelope, 4H), 2.04 (t, J = 6.0 Hz, 2H), 
2.25–2.45 (methylene envelope, 6H), 3.20 (t, J = 6.0 Hz, 2H), 3.30–3.42 (methylene envelope, 6H), 
3.70 (br s, 2H), 4.06 (t, J = 6.0 Hz, 2H), 4.38 (br s, 1H), 6.86 (d, J = 4.0 Hz, 1H), 7.01 (m, 5H), 7.26 
(d, J = 10.0 Hz, 1H), 7.39–7.46 (m, 5H); δC (methanol-d4) 25.0, 25.8, 28.2, 35.5, 38.1, 40.9, 41.8, 51.0, 
51.3, 65.2, 73.7, 113.0, 114.9 (d, J = 21.6 Hz), 115.8, 127.0, 127.6, 129.3 (d, J = 8.0 Hz), 132.4, 137.9 
(d, J = 3.0 Hz), 156.6, 157.2, 157.4, 161.9 (d, J = 244.5 Hz), 168.5, 173.6; m/z (ESI
+
, 50 eV): m/z (%): 
714.4 (10) [M + HCl]
+
, 678.4 (50) [M + H]
+
. HRMS (ESI
+
) [M + 2H + Cl]
+
 calcd for C35H47N9O3F2Cl 
714.3458 found 714.3462; HRMS (ESI
+
) [M + H]
+
 calcd for C35H46N9O3F2 678.3692 found 678.3685. 
6-Guanidino-N-(4-(3-guanidinopropoxy)-2-(4-phenylpiperidine-1-carbonyl)phenyl)hexanamide 
dihydrochloride (8c)  
The diguanidinium compound 8c was prepared from the diamine 7c according to the method used 
to prepare 8a. The product 8c was obtained as a semiglassy solid (45 mg, 56%); δH (methanol-d4) 1.47 
(m, 2H), 1.62 (m, 2H), 1.73 (methylene envelope, 4H), 1.96 (m, 1H), 2.07 (m, 2H), 2.40 (t, J = 7.2 Hz, 
2H), 2.83–2.91 (complex, 2H), 3.19 (t, J = 6.8 Hz, 2H), 3.41 (t, J = 6.8 Hz, 2H), 3.49 (m, 1H), 3.75 (br 
d, J=12.8 Hz, 1H), 4.11 (t, J = 5.6 Hz, 2H), 4.73 (br d, J = 11.6 Hz, 1H), 6.94 (s, 1H), 7.05 (dd, J = 2.8, 
8.8 Hz, 1H), 7.16–7.33 (complex, 6H); δC (methanol-d4) 26.3, 27.1, 29.54, 29.58, 33.9, 34.6, 36.7, 
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39.4, 42.2, 43.5, 66.4, 114.0, 116.9, 127.4, 127.7, 128.3, 129.0, 129.4, 134.1, 146.6, 158.0, 158.5, 
158.6, 169.8, 174.9; m/z (ESI
+
, 50 eV): m/z (%): 551.5 (30) [M + H]
+
 HRMS (ES
+
) [M + H]
+
 calcd for 
C29H43N8O3 551.3458 found 551.3431. 
N-(2-(4-(Benzo[d][1,3]dioxol-5-yl)methyl)piperazine-1-carbonyl)-4-(3-guanidinopropoxy) 
phenyl-6-guanidinohexanamide dihydrochloride (8d)  
The diguanidinium compound 8d was prepared from the diamine 7d according to the method used 
to prepare 8a. The product 8d was obtained as a glassy semisolid (50 mg, 93%); δH (methanol-d4) 
1.40–1.55 (methylene envelope, 2H), 1.55–1.74 (methylene envelope, 4H), 2.06 (m, 2H), 2.35 (t,  
J = 7.2 Hz, 2H), 2.43 (br s, 2H), 2.53 (br s, 2H), 3.17–3.26 (br t, J = 6.7 Hz, 2H), 3.34–3.43 (complex, 
4H), 3.50 (s, 2H), 3.71 (br s, 2H), 4.08 (m, 2H), 5.92 (s, 2H), 6.76 (br s, 2H), 6.86 (br s, 1H), 6.88 (d,  
J = 2.7 Hz, 1H), 7.04 (dd, J = 2.6, 8.8 Hz, 1H), 7.28 (d, J = 8.8 Hz, 1H); δC (methanol-d4) 26.4, 27.2, 
29.6, 36.9, 39.6, 42.4, 53.2, 53.4, 63.1, 66.6, 102.5, 109.0, 110.9, 114.3, 117.3, 124.3, 128.5, 129.0, 
131.0, 133.6, 148.7, 149.3, 158.1, 170.0, 174.9; m/z (ESI
+
, 50 eV): m/z (%): 610.5 (20) [M + H]
+
. 
HRMS (ES
+
) [M + H]
+
 calcd for C30H44N9O5 610.34 65 found 610.3474. 
3.2. Biology 
3.2.1. Cav2.2 Radioligand Displacement Assay 
Radioligand binding assays were run in triplicate in 96-well plates at room temperature as 
previously described [39]. Each assay contained the test compound, radiolabelled peptide  
(7 pM 
125
I-GVIA) and 8 μg of crude rat brain membrane, added last. All dilutions were made in assay 
buffer (20 mM HEPES, 75 mM NaCl, 0.2 mM EDTA, 0.2 mM EGTA, 2 μM Leupeptin, 2 μL 
apoprotinin (to 30 mL assay buffer) and 0.1% BSA, pH 7.4). The final volume in each well was 150 μL. 
After shaking for 1 h, the membrane was filtered (Wallac, Finland glass fibre filters pre-soaked in 
0.6% polyethyleneimine) and washed with 20 mM HEPES, 125 mM NaCl, pH 7.4 on a Tomtec 
harvester. After addition of scintillant, radioactivity bound to the filter was counted using a 1450 
MicroBeta (Wallac, Finland). The data was analyzed using GraphPad Prism 2.0 (GraphPad Software, 
Inc, San Diego, USA). 
3.2.2. Fluorescence Measurement of Calcium Responses 
SH-SY5Y cells were plated at a density of 30,000 cells/well on 384-well black-walled imaging 
plates and loaded for 30 min at 37 °C with Calcium 4 no-wash dye (Molecular Devices, Sunnyvale, 
CA) diluted in physiological salt solution (PSS; composition: 140 mM NaCl, 11.5 mM glucose,  
5.9 mM KCl, 1.4 mM MgCl2, 1.2 mM NaH2PO4, 5 mM NaHCO3, 1.8 mM CaCl2, 10 mM  
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.4). SH-SY5Y cells represent an 
attractive model system and express human Cav2.2 channels in a physiologically relevant context since 
in native, systems Cav channels are most likely co-expressed with auxiliary α2δ and β subunits. 
Calcium responses, elicited by addition of 90 mM KCl and 5 mM CaCl2 in the presence of 10 µM 
nifedipine, were measured using a FLIPR
TETRA
 fluorescent plate reader (excitation, 470–495 nm; 
emission, 515–575 nm) after 5 min pre-treatment with test compounds in PSS containing 1.8 mM 
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CaCl2. Under these conditions, the Ca
2+
 response elicited by addition of KCl/CaCl2 is mediated 
predominantly by GVIA-sensitive Cav2.2 [43]. ω-Conotoxin CVID (3 µM) was included as a positive 
control to define maximal inhibition of Cav2.2 responses. 
Fluorescent responses were plotted as response over baseline using ScreenWorks (Molecular 
Devices, version 3.1.1.4). Concentration-response curves of peak calcium responses, normalized to 
control responses, were generated using GraphPad Prism (Version 4.00, San Diego, California) using a 
4-parameter Hill equation with variable Hill slope fitted to the data. 
3.2.3. Patch Clamp Electrophysiology 
HEK293 cells stably expressing human Cav2.2 (α1B + α2δ + β3), were plated onto 12 mm coverslips 
and used for whole-cell patch clamp experiments [47]. Depolarization-activated calcium currents were 
obtained with the whole-cell recording configuration at room temperature (23–25 °C), using a 
MultiClamp 700B amplifier and pClamp9.2 software (Molecular Devices, Sunnyvale, CA). The 
external bath solution contained (in mM) 90 NaCl; 10 CaCl2; 1 MgCl2; 10 HEPES; 30 TEA-Cl;  
5 CsCl; 10 glucose, pH 7.4 with TEA-OH (~310 mOsmol/kg). The patch pipette had a resistance of  
1–3 MΩ, with an internal solution composed of (in mM) 130 K-Gluconate; 2 MgCl2; 5 EGTA;  
10 HEPES; 5 NaCl; 2 Mg-ATP; 1 Li-GTP, pH 7.2 with Cs-OH (~300 mOsmol/kg). Calcium currents 
were elicited from a holding potential of −80 mV with a depolarizing voltage step to a test potential of 
+20 mV for 150 ms, applied every 10 s. Bath perfusion was used to apply compounds, with series 
resistance typically compensated at 60%−80% and leak subtraction using a −P/4 pulse protocol.  
4. Conclusions  
The diphenylmethylpiperazine moiety is less likely to lead to toxic effects than the phenoxyaniline 
substituent present in previously investigated anthranilamide-based GVIA mimics: Anilides are listed 
in structural alerts for potential adverse drug effects [48] with hepatotoxicity of anilides in certain 
cases being linked to P-450 activation to benzoquinoneimines in humans [49]. It was therefore 
pleasing to see that mimics bearing the diphenylmethylpiperazine pharmacophore (7a, 7b, 8a, 8b) 
showed very similar activities in the radioligand displacement assay, and improved inhibition of 
intracellular calcium responses in SH-SY5Y cells, relative to the best of the phenoxyaniline-bearing 
compounds. Two sets of related compounds that did not possess the diphenylmethyl substituent (7c, 
7d, 8c, 8d) were inactive in the radioligand displacement assay, further suggesting that the 
diphenylmethyl moiety enhances calcium channel affinity in this class of compound. 
The radioligand displacement assay employing 
125
I-ω-conotoxin GVIA is thought to be a specific 
measure of binding affinity to Cav2.2 channels, because ω-conotoxin GVIA is exceptionally selective 
for this channel. As this assay does not measure the actual passage of Ca
2+
 ions though the channel, 
there is always the possibility that test compounds could cause the 
125
I-ω-conotoxin to be released from 
the channel through, for example, an allosteric effect, without actually inhibiting the channel. It was 
therefore also very pleasing to find that ω-conotoxin GVIA mimetics (7c, 7d, 8c, 8d) identified to be 
active in the radioligand displacement assay also induced functional inhibition of intracellular calcium 
responses in SH-SY5Y neuroblastoma cells and calcium currents in HEK293 cells stably expressing 
human Cav2.2 channels. These data fill an important gap between binding and downstream functional 
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inhibition on median nerve-stimulated rat vas deferans that we have previously observed [50]. These 
results therefore validate both the use of ω-conotoxin GVIA as a starting point for the design of Cav2.2 
channel blockers and the use of the radioligand displacement assay as an initial screening tool for 
Cav2.2 activity.  
The results from the functional assays show the difluoro, diguanidino compound 8b to be the most 
effective Cav2.2 channel blocker of the compounds examined in this study. The results obtained with 
this compound will form the basis for further optimization work, with the aim of improving potency 
and incorporating more drug-like properties. 
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